Company Encyclopedia
View More
name
Blackrock Future Health ETF
BMED.US
News
View More

Medtronic PLC $MDT Shares Purchased by CW Advisors LLC

CW Advisors LLC increased its holdings in Medtronic PLC by 39.9% in Q2, owning 80,164 shares worth $6,988,000. Analysts have raised price targets for Medtronic, with Citigroup, Morgan Stanley, and others giving 'buy' and 'overweight' ratings. Medtronic reported Q2 earnings of $1.36 per share, beating estimates, and announced a quarterly dividend of $0.71 per share. The stock has an average rating of 'Moderate Buy' with a target price of $110.44.

Market Beat·
US
MDT
+0.02%
Market Beat·
US
MDT
+0.02%

Glucose monitor problems linked with deaths, injuries: FDA

The FDA has linked at least seven deaths and hundreds of injuries to malfunctioning glucose monitors by Abbott Diabetes Care. The issue affects about 3 million FreeStyle Libre 3 and Libre 3 Plus devices, traced to one production line. Incorrect low glucose readings may lead to serious health risks. Abbott has reported 736 severe adverse events and is replacing affected sensors. The company has identified the issue's source and expects no major supply disruptions.

Thehill·
US
ABT
+0.09%
Thehill·
US
ABT
+0.09%

Certain Common Stock of Guardant Health, Inc. are subject to a Lock-Up Agreement Ending on 5-DEC-2025.

Guardant Health, Inc.'s common stock is subject to a lock-up agreement ending on December 5, 2025. The lock-up period lasts 31 days, from November 4 to December 5, 2025. During this time, directors and executive officers cannot sell or transfer shares without consent from Goldman Sachs & Co. LLC and Jefferies LLC, with specified exceptions.

marketscreener·
US
GH
+2.42%
marketscreener·
US
GH
+2.42%

Medtronic (MDT) Maintains Quarterly Dividend of $0.71 Per Share

Medtronic plc (MDT) has maintained its quarterly dividend of $0.71 per share, offering a forward yield of 2.78%. The company demonstrates strong financial health with consistent revenue growth, robust profitability metrics, and a solid balance sheet. While valuation metrics are near historical highs, analyst sentiment remains positive, suggesting market confidence in the medical device giant.

GuruFocus·
US
MDT
+0.02%
GuruFocus·
US
MDT
+0.02%

Gilead Sciences Inc. Stock Underperforms Thursday When Compared To Competitors

Gilead Sciences Inc. (GILD) shares fell 1.90% to $122.62 on Thursday, underperforming compared to competitors. The S&P 500 Index rose 0.11%, while the Dow Jones Industrial Average fell 0.07%. Gilead's stock is 4.72% below its 52-week high. Trading volume was 4.9M, below the 50-day average of 7.3M. Competitors' performances: Johnson & Johnson (JNJ) fell 1.39%, Pfizer Inc. (PFE) rose 0.51%, and Abbott Laboratories (ABT) rose 0.09%. Data source: Dow Jones Market Data, FactSet. Compiled December 4, 2025.

Dow Jones·
US
GILD
-1.90%
Dow Jones·
US
GILD
-1.90%
© 2025 Longbridge｜Disclaimer